These authors contributed equally to this work.
Prognostic relevance of BRD7 expression in colorectal carcinoma
Article first published online: 7 DEC 2012
© 2012 The Authors. European Journal of Clinical Investigation © 2012 Stichting European Society for Clinical Investigation Journal Foundation
European Journal of Clinical Investigation
Volume 43, Issue 2, pages 131–140, February 2013
How to Cite
Eur J Clin Invest 2013; 43 (2): 131–140
- Issue published online: 18 JAN 2013
- Article first published online: 7 DEC 2012
- Accepted manuscript online: 12 NOV 2012 06:22AM EST
- Manuscript Accepted: 7 NOV 2012
- Manuscript Received: 10 OCT 2012
- colorectal cancer
BRD7 is a member of bromodomain-containing protein and was found to be a cofactor of P53. Down-regulation of BRD7 has been shown in nasopharyngeal carcinoma cell lines and tissues. However, the clinical role of BRD7 in colorectal cancer remains unknown.
Materials and methods
Real-time PCR, Western blotting analysis and immunohistochemistry were employed to examine BRD7 expression in CRC cell lines/tissues compared with normal epithelia cells/adjacent non-tumorous tissues. In addition, statistical analyses were applied to evaluate the diagnostic value and associations of BRD7 expression with clinical parameters of patient samples.
BRD7 was down-regulated in colorectal cancer cell lines and cancerous tissues compared with that in normal colon epithelial cells and adjacent noncancerous tissue samples. BRD7 protein expression was positively correlated with clinical stage (P < 0·001), T classification (P = 0·001), N classification (P < 0·001), M classification (P < 0·001) and pathologic differentiation (P = 0·008). Patients with low/none BRD7 expression had shorter overall survival time than those with higher BRD7 expression. Univariate and multivariate analyses indicated BRD7 expression was an independent prognostic factor (P < 0·001).
BRD7 may serve as a potential prognostic biomarker of human colorectal cancer.